Clinical-stage biotech Relay Therapeutics (RLAY) is set to raise $275 million in a public stock offering, shoring up its balance sheet to advance a pipeline of precision cancer therapies led by its PI3Kα inhibitor, zovegalisib.
The offering is being managed by a syndicate of prominent banks, with Jefferies, TD Cowen, Goldman Sachs & Co. LLC and Guggenheim Securities acting as joint book-running managers. Raymond James is acting as lead manager.
The Cambridge, Massachusetts-based company priced 22,916,667 shares of its common stock at $12.00 per share. Underwriters also have a 30-day option to purchase up to an additional 3,437,500 shares, which could increase the total proceeds.
For investors, the capital infusion provides a crucial cash runway to fund expensive late-stage clinical trials, but it also comes at the cost of dilution for existing shareholders. The offering price of $12.00 represents a discount to recent trading levels, and the stock declined in pre-market trading following the announcement.
Relay's approach centers on its Dynamo® platform, which uses computational and experimental methods to design drugs for previously intractable protein targets. The company's lead asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor and is currently in a Phase 3 trial for HR+/HER2- metastatic breast cancer, a common form of the disease driven by mutations in the PIK3CA gene.
The proceeds from this offering are critical for funding the ongoing ReDiscover-2 Phase 3 trial and supporting the development of zovegalisib for genetic diseases. Beyond its lead candidate, Relay's pipeline also includes programs for NRAS-driven solid tumors and Fabry disease, a rare genetic disorder.
The $275 million raise significantly extends Relay's financial runway, a key metric for pre-revenue biotech firms. While the immediate market reaction reflects the dilutive impact of the new shares, the funding is a necessary step to move its lead drug through the final stages of clinical testing and toward potential commercialization.
This article is for informational purposes only and does not constitute investment advice.
